Henry Schein (NASDAQ:HSIC – Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 5.420-5.480 for the period, compared to the consensus earnings per share estimate of 5.540. The company issued revenue guidance of $13.8 billion-$13.9 billion, compared to the consensus revenue estimate of $13.8 billion.
Henry Schein Price Performance
Shares of Henry Schein stock opened at $84.96 on Tuesday. Henry Schein has a twelve month low of $68.70 and a twelve month high of $92.18. The company has a quick ratio of 0.76, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $85.81 and a two-hundred day simple moving average of $81.59. The stock has a market capitalization of $9.39 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.87.
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.20. The firm had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Henry Schein had a net margin of 3.07% and a return on equity of 16.39%. The company’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.38 earnings per share. Analysts forecast that Henry Schein will post 5.55 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts have commented on HSIC shares. Piper Sandler boosted their price target on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Stifel Nicolaus set a $95.00 price objective on shares of Henry Schein in a research note on Wednesday, August 5th. UBS Group lifted their price objective on shares of Henry Schein from $94.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Barrington Research set a $104.00 target price on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, August 21st. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Henry Schein presently has an average rating of “Moderate Buy” and an average target price of $93.57.
Get Our Latest Analysis on Henry Schein
More Henry Schein News
These are some of the HSIC news items that stood out recently:
- Neutral Sentiment: Henry Schein expects 2026 revenue of $13.8 billion to $13.9 billion, broadly in line with the $13.8 billion consensus estimate. Henry Schein lowers 2026 adjusted EPS guidance following change to non-GAAP reporting
- Negative Sentiment: 2026 adjusted EPS guidance is now $5.42–$5.48, below the cited analyst consensus of $5.54. The lowered outlook is the main potential pressure on HSIC shares, though the company linked the update to its non-GAAP reporting presentation. Henry Schein cuts FY2026 non-GAAP EPS guidance on accounting change
Henry Schein Company Profile
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Further Reading
- Five stocks we like better than Henry Schein
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
